Universe Pharmaceuticals Inc.
UPC · NASDAQ
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $9,153 | $10,140 | $12,884 | $13,842 |
| % Growth | -9.7% | -21.3% | -6.9% | – |
| Cost of Goods Sold | $5,988 | $7,313 | $9,640 | $9,778 |
| Gross Profit | $3,165 | $2,827 | $3,245 | $4,063 |
| % Margin | 34.6% | 27.9% | 25.2% | 29.4% |
| R&D Expenses | $97 | $2,956 | $87 | $2,613 |
| G&A Expenses | $0 | $3,189 | $0 | $0 |
| SG&A Expenses | $5,394 | $5,592 | $4,852 | $5,058 |
| Sales & Mktg Exp. | $0 | $7,255 | $0 | $0 |
| Other Operating Expenses | $0 | $559 | $46 | $69 |
| Operating Expenses | $5,491 | $9,107 | $4,985 | $7,739 |
| Operating Income | -$2,327 | -$6,280 | -$1,740 | -$3,676 |
| % Margin | -25.4% | -61.9% | -13.5% | -26.6% |
| Other Income/Exp. Net | -$958 | $10,595 | -$10,696 | -$464 |
| Pre-Tax Income | -$3,285 | $4,316 | -$12,436 | -$4,140 |
| Tax Expense | $0 | -$58 | $665 | $1,339 |
| Net Income | -$3,285 | $4,374 | -$13,101 | -$5,448 |
| % Margin | -35.9% | 43.1% | -101.7% | -39.4% |
| EPS | -944.4 | 719.79 | -2,155.91 | -919.74 |
| % Growth | -231.2% | 133.4% | -134.4% | – |
| EPS Diluted | -944.4 | 719.79 | -2,155.91 | -919.74 |
| Weighted Avg Shares Out | 3 | 6 | 6 | 6 |
| Weighted Avg Shares Out Dil | 3 | 6 | 6 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $129 | $142 | $137 | $82 |
| Depreciation & Amortization | $270 | $237 | $249 | $251 |
| EBITDA | -$2,886 | $4,694 | -$12,051 | -$3,806 |
| % Margin | -31.5% | 46.3% | -93.5% | -27.5% |